{"id":864536,"date":"2025-06-27T08:05:10","date_gmt":"2025-06-27T12:05:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-unveils-nugevia-glo-a-breakthrough-in-cellular-skin-health-backed-by-patented-pharmaceutical-science\/"},"modified":"2025-06-27T08:05:10","modified_gmt":"2025-06-27T12:05:10","slug":"jupiter-neurosciences-unveils-nugevia-glo-a-breakthrough-in-cellular-skin-health-backed-by-patented-pharmaceutical-science","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-unveils-nugevia-glo-a-breakthrough-in-cellular-skin-health-backed-by-patented-pharmaceutical-science\/","title":{"rendered":"Jupiter Neurosciences Unveils Nugevia\u2122 GLO: A Breakthrough in Cellular Skin Health, Backed by Patented Pharmaceutical Science"},"content":{"rendered":"
\n

\n
\n GLO targets the growing \u201dbeauty-from-within\u201d market with scientifically proven cellular defense and skin vitality benefits<\/em>
\n <\/strong>\n <\/p>\n

Jupiter, Florida, June 27, 2025 (GLOBE NEWSWIRE) — Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL\u2122, a proprietary resveratrol-based platform, is pleased to unveil Nugevia\u2122 GLO\u2014a pioneering “beauty-from-within” supplement designed to elevate the standard of skin health through clinically validated cellular science. GLO is a daily supplement designed to support radiant, resilient skin from the inside out by promoting cellular defense, collagen integrity, and hydration.<\/p>\n

\n Unmatched Science Meets a Booming Market<\/strong>\n <\/p>\n

“With Nugevia GLO, we’re taking our proprietary science to a broader audience,” said Christer Ros\u00e9n, Chairman and CEO of Jupiter Neurosciences. “GLO is not just another beauty supplement\u2014it’s a clinically grounded formulation that enhances skin vitality by working at the cellular level. We’re unlocking a high-growth vertical in the $8 trillion longevity market while continuing to advance our pharmaceutical pipeline.”<\/p>\n

Nugevia GLO leverages the potent synergy of JOTROL\u2122, Jupiter’s clinically validated resveratrol delivery technology, and NovaSOL\u00ae Astaxanthin, a powerful antioxidant known for its skin-enhancing properties. The product will be available via direct-to-consumer e-commerce platforms beginning Fall 2025.<\/p>\n

JOTROL\u2122, which demonstrated a nine-fold increase in resveratrol bioavailability in Phase I trials, is central to Jupiter’s ongoing CNS clinical programs. When combined with Astaxanthin\u2014shown to improve skin elasticity, hydration, and pigmentation\u2014the resulting formulation creates a best-in-class solution for skin health and systemic rejuvenation.<\/p>\n

\n High-Margin, High-Impact<\/strong>\n <\/p>\n

The GLO product launch is part of Jupiter’s strategic shift into consumer wellness as a parallel growth engine to its therapeutic portfolio. Priced as a premium supplement, GLO represents a high-margin revenue stream with broad demographic appeal, including women over 35 seeking proactive skin and aging solutions grounded in real science.<\/p>\n

Jupiter anticipates that the Nugevia rollout, including GLO, PWR and MND, will drive significant top-line growth and serve as a self-reinforcing capital engine. Revenues from GLO and the broader Nugevia line are expected to support clinical development, reduce capital dependency, and increase long-term shareholder value.<\/p>\n

Nugevia GLO is a two-capsule-per-day regimen designed for optimal absorption and compliance. Key benefits include:<\/p>\n